Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
about
New viruses for cancer therapy: meeting clinical needsOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsCalcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesEngineered adenovirus serotypes for overcoming anti-vector immunity.Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.Serotype chimeric human adenoviruses for cancer gene therapy.Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.Oncolytic adenovirus based on serotype 3.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration
P2860
Q24567699-494EA5B1-3B09-4304-8608-85ACDD7F6589Q26776553-CE845057-8EF9-404B-BF4A-F12B9BE9E675Q33711997-DEEF4C07-3DDE-4C9E-9E4A-8F7B0820584FQ34178183-1856B96B-2752-4B1B-988E-6D74FC1A58EDQ35238258-D4D0454F-CA87-4E63-964D-C689C35B7606Q35717021-72FD41D3-5973-482C-9A77-97125DEFF83AQ36664201-86353B21-D36B-4A8D-9A46-9F279344C41FQ37567831-21408ABD-AE95-4106-9C4F-91957CE22C1CQ37603360-4DCE7092-43A7-4048-AACD-5FBAD5939DEFQ37945193-22AED461-7D29-413C-8018-4D791A32A1E5Q38875030-C4DEB931-D987-490E-8956-D84D745D873CQ39004582-C3A94107-FDCC-47DE-BF22-09AD0856274AQ39616158-38B1BFD7-9916-45D7-BAB2-2E29696EF7E2Q40087457-499AEFE2-A4BF-4888-B8BB-1914BC7C2FEEQ45869559-2416391F-6FE1-4F98-8D31-501F2FBFDFA3Q58770917-2E1A65F1-3BC7-440B-B5AD-7B524D2B7D57
P2860
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@en
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@nl
type
label
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@en
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@nl
prefLabel
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@en
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@nl
P2093
P2860
P356
P1433
P1476
Changing the adenovirus fiber ...... ce of neutralizing antibodies.
@en
P2093
A Hemminki
M Särkioja
M T Ahonen
T Hakkarainen
P2860
P2888
P304
P356
10.1038/GT.2008.56
P577
2008-04-10T00:00:00Z
P5875
P6179
1040355807